

LABOMAR S.P.A.: 2022 FINANCIAL CALENDAR

Istrana, January 19th, 2022 – Labomar S.p.A., company listed on Euronext Growth Milan market, announces the following financial calendar relating to corporate events 2022:

DATE	EVENT
20-Jan-22	2021 Consolidated Revenues Labomar Group – Preliminary figures
30-Mar-22	Board of Directors' meeting to approve the separate Financial Statements of the Company and the Consolidated Statements of the Group for the year ended December 31, 2021
22-Apr-22	1Q 2022 Consolidated Revenues Labomar Group – Preliminary figures
29-Apr-22	First call for the shareholders' meeting to approve the Separate Financial Statements of the Company and present the Consolidated Statements of the Group for the year ended December 31, 2021
6-May-22	Second call for the shareholders' meeting to approve the Separate Financial Statements of the Company and present the Consolidated Statements of the Group for the year ended December 31, 2021
25-July-22	1H 2022 Consolidated Revenues Labomar Group – Preliminary figures
29-Sept-22	Board of Directors' meeting to approve the Consolidated half-year report as at 30 June, 2022
20-Oct-22	3Q 2022 Consolidated Revenues Labomar Group – Preliminary figures

Any additional variation to the dates indicated above will be promptly communicated.

Labomar profile

Founded by Walter Bertin in Istrana (province of Treviso) in 1998, Labomar is specialised in the development and production of food supplements, medical devices, foods for special medical purposes and cosmetics for third parties. Over more than 20 years, Labomar has built a business model which sets it apart from its competitors and generates value for all stakeholders, providing a comprehensive service and a high quality and productivity standard. The company boasts a well structured and cutting-edge research and development department with a particular focus on innovation, a commercial team which reacts quickly to market demands and a high level of product differentiation thanks to its proprietary patents and formulas.

In July 2021, Labomar acquired 63% of the Welcare Group. The Group comprises Welcare Industries Spa and Welcare Research Srl, producers of skincare medical devices, with its registered office in Orvieto. In December 2021, the holding increased to 70%.

In November 2021, LaboVar Srl was established - 51% owned by Labomar and 49% by Var Group Spa (a wholly-owned subsidiary of the listed STAR Sesa Spa) - for the sale of nutraceutical products on an e-commerce platform in the Chinese market.

Also in November 2021, Labomar acquired full control of Labiotre Srl, a Tuscan enterprise specialising in the production of plant extracts, fully integrating the supply chain concept advocated by Labomar.

Labomar sincerely believes in operating as a business centred on sustainability and the well-being of the individual, the environment and the community. It has therefore amended its By-Laws to become a Benefit company. This new legal status, introduced in Italy in 2016, formalises the decision to develop a responsible, sustainable and transparent development model, which marries operating-earnings objectives with social and environmental aspects.

For further information:

Labomar Press Office

Thanai Bernardini - +39.335.7245418 - me@thanai.it

Alessandro Bozzi Valenti - +39.348.0090866 - alessandro.valenti@thanai.it

Investor Relations Labomar

Claudio De Nadai - +39.0422.677203 - claudio.denadai@labomar.com

Mara Di Giorgio - +39 335 7737417 - mara@twin.services

Euronext Growth Advisor

Banca Mediolanum - +39 02 9049 2525 - ecm@mediolanum.it